In this section of exploration, they added primary TMZ resistance models using CRISPR‐induced knockout of MSH6 of GBM cells and treatment‐induced TMZ resistance models using increased dosages of TMZ to treat and select the live GBM cells. This evidence concerns the gene MSH6 and glioblastoma.